185 related articles for article (PubMed ID: 29143776)
1. Gastric Cancer Cell Glycosylation as a Modulator of the ErbB2 Oncogenic Receptor.
Duarte HO; Balmaña M; Mereiter S; Osório H; Gomes J; Reis CA
Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29143776
[TBL] [Abstract][Full Text] [Related]
2. ST6Gal1 targets the ectodomain of ErbB2 in a site-specific manner and regulates gastric cancer cell sensitivity to trastuzumab.
Duarte HO; Rodrigues JG; Gomes C; Hensbergen PJ; Ederveen ALH; de Ru AH; Mereiter S; Polónia A; Fernandes E; Ferreira JA; van Veelen PA; Santos LL; Wuhrer M; Gomes J; Reis CA
Oncogene; 2021 May; 40(21):3719-3733. PubMed ID: 33947960
[TBL] [Abstract][Full Text] [Related]
3. Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems.
Chang HR; Park HS; Ahn YZ; Nam S; Jung HR; Park S; Lee SJ; Balch C; Powis G; Ku JL; Kim YH
BMC Cancer; 2016 Mar; 16():200. PubMed ID: 26955870
[TBL] [Abstract][Full Text] [Related]
4. O-glycans truncation modulates gastric cancer cell signaling and transcription leading to a more aggressive phenotype.
Freitas D; Campos D; Gomes J; Pinto F; Macedo JA; Matos R; Mereiter S; Pinto MT; Polónia A; Gartner F; Magalhães A; Reis CA
EBioMedicine; 2019 Feb; 40():349-362. PubMed ID: 30662000
[TBL] [Abstract][Full Text] [Related]
5. Contribution of PGAP3 co-amplified and co-overexpressed with ERBB2 at 17q12 involved poor prognosis in gastric cancer.
Wang D; Hao S; He H; Zhang J; You G; Wu X; Zhang R; Meng X; Cui X; Bai J; Fu S; Yu J
J Cell Mol Med; 2023 Aug; 27(16):2424-2436. PubMed ID: 37386793
[TBL] [Abstract][Full Text] [Related]
6. Glycomic analysis of gastric carcinoma cells discloses glycans as modulators of RON receptor tyrosine kinase activation in cancer.
Mereiter S; Magalhães A; Adamczyk B; Jin C; Almeida A; Drici L; Ibáñez-Vea M; Gomes C; Ferreira JA; Afonso LP; Santos LL; Larsen MR; Kolarich D; Karlsson NG; Reis CA
Biochim Biophys Acta; 2016 Aug; 1860(8):1795-808. PubMed ID: 26721331
[TBL] [Abstract][Full Text] [Related]
7. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.
Patel D; Bassi R; Hooper A; Prewett M; Hicklin DJ; Kang X
Int J Oncol; 2009 Jan; 34(1):25-32. PubMed ID: 19082474
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
9. Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma.
Kim J; Fox C; Peng S; Pusung M; Pectasides E; Matthee E; Hong YS; Do IG; Jang J; Thorner AR; Van Hummelen P; Rustgi AK; Wong KK; Zhou Z; Tang P; Kim KM; Lee J; Bass AJ
J Clin Invest; 2014 Dec; 124(12):5145-58. PubMed ID: 25401468
[TBL] [Abstract][Full Text] [Related]
10. Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells.
Zheng Y; Izumi K; Yao JL; Miyamoto H
Endocr Relat Cancer; 2011 Aug; 18(4):451-64. PubMed ID: 21613411
[TBL] [Abstract][Full Text] [Related]
11. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
12. The impact of Helicobacter pylori on EGF, EGF receptor, and the c-erb-B2 expression.
Jurkowska G; Piotrowska-Staworko G; Guzińska-Ustymowicz K; Kemona A; Świdnicka-Siergiejko A; Łaszewicz W; Dąbrowski A
Adv Med Sci; 2014 Sep; 59(2):221-6. PubMed ID: 25051417
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab Inhibits Growth of HER2-Negative Gastric Cancer Cells Through Gastrin-Initialized CCKBR Signaling.
Cui Y; Li SB; Peng XC; Wu J; Fu GH
Dig Dis Sci; 2015 Dec; 60(12):3631-41. PubMed ID: 26173505
[TBL] [Abstract][Full Text] [Related]
14. miR 1296-5p Inhibits the Migration and Invasion of Gastric Cancer Cells by Repressing ERBB2 Expression.
Shan X; Wen W; Zhu D; Yan T; Cheng W; Huang Z; Zhang L; Zhang H; Wang T; Zhu W; Zhu Y; Zhu J
PLoS One; 2017; 12(1):e0170298. PubMed ID: 28099468
[TBL] [Abstract][Full Text] [Related]
15. Controlled activation of ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: implications for progression of ErbB2-overexpressing tumors.
Zhan L; Xiang B; Muthuswamy SK
Cancer Res; 2006 May; 66(10):5201-8. PubMed ID: 16707444
[TBL] [Abstract][Full Text] [Related]
16. Integrated Proteomic and Genomic Analysis of Gastric Cancer Patient Tissues.
Yan JF; Kim H; Jeong SK; Lee HJ; Sethi MK; Lee LY; Beavis RC; Im H; Snyder MP; Hofree M; Ideker T; Wu SL; Paik YK; Fanayan S; Hancock WS
J Proteome Res; 2015 Dec; 14(12):4995-5006. PubMed ID: 26435392
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory cytokines regulate the expression of glycosyltransferases involved in the biosynthesis of tumor-associated sialylated glycans in pancreatic cancer cell lines.
Bassagañas S; Allende H; Cobler L; Ortiz MR; Llop E; de Bolós C; Peracaula R
Cytokine; 2015 Sep; 75(1):197-206. PubMed ID: 25934648
[TBL] [Abstract][Full Text] [Related]
18. NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation.
Van Laere SJ; Van der Auwera I; Van den Eynden GG; van Dam P; Van Marck EA; Vermeulen PB; Dirix LY
Br J Cancer; 2007 Sep; 97(5):659-69. PubMed ID: 17700572
[TBL] [Abstract][Full Text] [Related]
19. Premature senescence is a primary fail-safe mechanism of ERBB2-driven tumorigenesis in breast carcinoma cells.
Trost TM; Lausch EU; Fees SA; Schmitt S; Enklaar T; Reutzel D; Brixel LR; Schmidtke P; Maringer M; Schiffer IB; Heimerdinger CK; Hengstler JG; Fritz G; Bockamp EO; Prawitt D; Zabel BU; Spangenberg C
Cancer Res; 2005 Feb; 65(3):840-9. PubMed ID: 15705882
[TBL] [Abstract][Full Text] [Related]
20. MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistance.
Paulson AK; Linklater ES; Berghuis BD; App CA; Oostendorp LD; Paulson JE; Pettinga JE; Melnik MK; Vande Woude GF; Graveel CR
Mol Cancer Res; 2013 Sep; 11(9):1112-21. PubMed ID: 23825050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
